• Home
  • About
  • News & Resources
  • Expert interviews
  • Patient case studies
    • Recurrence risk
    • Treatment options
  • Shared decision making
  • Faculty
Menu
  • Home
  • About
  • News & Resources
  • Expert interviews
  • Patient case studies
    • Recurrence risk
    • Treatment options
  • Shared decision making
  • Faculty
Login
Logout
Menu

POSITIVE study provides reassurance regarding ET interruption to attempt pregnancy

Home Posts tagged “News Article”
Home » Posts Tagged "News Article"
13 Dec
News & Resources

POSITIVE study provides reassurance regarding ET interruption to attempt pregnancy

  • 13 December 2022
  • By Chris Norris

medwireNews: Temporarily withholding adjuvant endocrine therapy (ET) to attempt pregnancy does not adversely impact the short-term disease outcomes of women with hormone receptor-positive early breast cancer, indicate POSITIVE data.

Continue reading

12 Dec
News & Resources

monarchE 4-year analysis shows deepening iDFS benefits with abemaciclib use

  • 13 December 2022
  • By Chris Norris

medwireNews: Interim analysis of the monarchE trial indicates that the invasive disease-free survival (iDFS) benefits of adding adjuvant abemaciclib to endocrine therapy have strengthened after 4 years of follow-up in patients with high-risk, hormone receptor-positive, HER2-negative, early breast cancer.

Continue reading

08 Dec
News & Resources

RxPONDER points to biologic underpinnings for racial disparities in early breast cancer

  • 13 December 2022
  • By Chris Norris

medwireNews: Non-Hispanic Black women with hormone receptor-positive, HER2-negative, early breast cancer have worse outcomes than their non-Hispanic White counterparts despite similar genetic risk and treatment adherence in the first year, suggests an analysis of the RxPONDER trial.

Continue reading

07 Dec
News & Resources

21-gene expression assay not prognostic for young, luminal B subtype early breast cancer patients

  • 7 December 2022
  • By Chris Norris

medwireNews: The 21-gene expression assay may be a poor prognostic aid for premenopausal women aged less than 40 years with luminal B subtype, hormone receptor-positive, HER2-negative early breast cancer, indicates research presented at the ESMO Asia Congress 2022 in Singapore.

Continue reading

06 Dec
News & Resources

Diarrhea main PRO concern for abemaciclib use in Chinese early breast cancer patients

  • 6 December 2022
  • By Chris Norris

medwireNews: Analysis of the monarchE trial suggests that an increase in the burden of diarrhea is the only patient-reported outcome (PRO) to be adversely affected by the addition of abemaciclib to standard endocrine therapy (ET) in Chinese patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer.

Continue reading

21 Sep
News & Resources

Final GIM2 analysis consolidates dose-dense adjuvant chemotherapy for early breast cancer

  • 19 October 2022
  • By Chris Norris

medwireNews: Dose-dense adjuvant chemotherapy significantly improves the outcomes of individuals with node-positive, early-stage breast cancer relative to the standard schedule, confirm the end-of-study findings from GIM2 presented at the ESMO Congress 2022 in Paris, France.

Continue reading

16 Sep
News & Resources

Extended AI therapy ‘not recommended’ for all postmenopausal breast cancer patients

  • 20 September 2022
  • By Chris Norris

medwireNews: The 10-year findings from the DATA trial have shown no significant benefit of extending aromatase inhibitor (AI) treatment beyond 5 years of sequential therapy in the full study population of postmenopausal women with hormone receptor-positive breast cancer.

Continue reading

21 Jun
News & Resources

Factors associated with abemaciclib discontinuation in monarchE identified

  • 20 September 2022
  • By admin

medwireNews: The monarchE investigators have identified baseline factors linked to an increased risk for discontinuation of abemaciclib in the trial comprising patients with hormone receptor-positive, HER2-negative early breast cancer.

Continue reading

10 Jun
News & Resources

ctDNA may serve as a marker for late recurrence in high-risk HR-positive breast cancer

  • 20 September 2022
  • By admin

medwireNews: Plasma circulating tumor (ct)DNA analysis could help identify patients with hormone receptor (HR)-positive, HER2-negative early breast cancer who are likely to have distant recurrence at 5 years or more after diagnosis despite receipt of adjuvant therapy, indicate CHiRP study results.

Continue reading

10 Jun
News & Resources

Low-risk luminal A breast cancer patients may be able to forgo radiotherapy

  • 20 September 2022
  • By admin

medwireNews: Combining clinicopathologic factors with the luminal A subtype could help identify women with a very low risk for breast cancer local recurrence after breast-conserving surgery, making them good candidates for adjuvant radiotherapy omission, suggests the LUMINA study.

Continue reading

Load more posts
Loading...


Email: [email protected]
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK


Funding

This program is supported by an educational grant from Lilly.
Recent Posts
  • ESMO_SABCS_Interview_Banners_MM Fbox 2 1000x565
    SABCS 2022: Implications for early breast cancer
    21 December 2022 No Comments
  • Scan
    POSITIVE study provides reassurance regarding ET interruption to attempt pregnancy
    13 December 2022 No Comments
  • Breast scan image
    monarchE 4-year analysis shows deepening iDFS benefits with abemaciclib use
    12 December 2022 No Comments
Site Navigation
  • Home
  • About
  • News & Resources
  • Expert interviews
  • Patient case studies
    • Recurrence risk
    • Treatment options
  • Shared decision making
  • Faculty
  • Privacy Policy
  • Terms and Conditions

© 2022 Springer Healthcare is part of the Springer Nature Group
Create your first navigation menu here

Login / register

Login

Forgot Password

Not registered yet? Register here

"*" indicates required fields

Consent*
Healthcare Professional

Menu
  • Home
  • About
  • News & Resources
  • Expert interviews
  • Patient case studies
    • Recurrence risk
    • Treatment options
  • Shared decision making
  • Faculty
Login / Register

Can you spare 2 minutes to share some feedback?

Click here to take the short survey
No thanks, not at this time
  • English